Table 1.

Comparison of the therapeutic outcomes in each HAIC regimen

Regimens	CDDP monotherapy	Low-dose FP	FAIT	New FP/ the controlled arm (sorafenib)	FOLFOX plus sorafenib/ the controlled arm (sorafenib)
Treatment line	1st	1st	1st	1st	1st
CR rate	4.1%	4.0–8.0%	16.4%	19.2–29.0 %/0%	8.0%/0%
Response rate	3.6–37%	24.5–71%	24.6–57%	71.0–86.3%/10%	40–54.4%/2.4%
Progression-free survival	3.1 M	4.1–7.0 M	3.3–5.5 M	8.0–9.5 M/5.1 M	7.1–8.6 M/2.6 M
Overall survival	2.5–10.7 M	6.0–15.9 M	6.9–11.8 M	27.0–33.0 M/13.2 M	13.4–14.5 M/7.1 M

HAIC, hepatic arterial infusion chemotherapy; CDDP, cisplatin; FP, cisplatin plus 5-fluorouracil; FAIT, 5-FU arterial infusion plus interferon therapy; FOLFOX, Folinic acid, 5-fluorouracil, and Oxaliplatin; CR, complete response.